Meril’s MeRes100 stent receives CE markOctober 8, 2019
Meril Life Sciences said its indigenously designed and manufactured scaffold MeRes100 BRS thin strut bioresorbable scaffold received CE marking.
Metallic drug-eluting stents (DES) are associated with incremental risk of clinical or adverse events: on an average, 2% to 3% of patients with metallic DES implants may require a repeat intervention year on year.
MeRes100 was designed as a solution to bridge this gap between the temporary treatment horizon for opening a blockage and the undesirably permanent nature of a metallic DES implant.
Across clinical trials, MeRes-1 (the first in-human study conducted in India) and MeRes-1 Extend (conducted in Brazil, Europe and Asia), MeRes100 BRS has shown long-term positive safety and sustained efficacy outcomes for patients with coronary artery disease in treatment of de-novo coronary artery lesions, the company said in a statement.